EmeraNova Launches Catalyst Accelerator to Advance Startups in Tissue Restoration and Advanced Wound Care
EmeraNova™, a Phoenix-based medical technology company specializing in advanced tissue restoration technologies, has launched Catalyst, a four-month accelerator program designed to identify and support emerging companies developing innovations in tissue restoration, advanced wound care and regenerative medicine.
Through Catalyst, an EmeraNova™ Accelerator, the company aims to help promising startups overcome the challenges that often prevent innovative healthcare technologies from progressing beyond early development and reaching patients. The program will offer participating companies structured validation, expert mentorship, commercialization guidance and potential investment opportunities to help advance their technologies toward broader market adoption.
Applications for the accelerator are now open. EmeraNova is seeking companies operating in the medical technology, biotechnology and pharmaceutical sectors that have demonstrated proof of concept and progressed into later stages of development. The initiative is intended to support founders as they navigate the technical, regulatory, clinical, operational and commercial considerations involved in bringing healthcare innovations to market.
The launch reflects EmeraNova’s broader commitment to identifying promising technologies and helping translate scientific and engineering advances into practical solutions for healthcare providers and patients. By working with startups earlier in their development journeys, the company hopes to identify potential obstacles before they become significant barriers to commercialization.
Addressing the Gap Between Healthcare Innovation and Commercialization
Despite continued progress in medical research and technology development, many promising healthcare innovations never reach routine clinical use. Startups may demonstrate encouraging proof-of-concept results but encounter difficulties when moving toward regulatory clearance, clinical validation, manufacturing, investment and commercial distribution.
These challenges are particularly relevant in tissue restoration, advanced wound care and regenerative medicine, where technologies often require specialized clinical evidence, regulatory planning and integration into existing care pathways. A promising technology may offer scientific potential, but its successful commercialization also depends on demonstrating practical value, meeting healthcare requirements and securing the resources needed to scale.
EmeraNova developed Catalyst in response to this gap. Rather than focusing exclusively on providing capital, the accelerator will emphasize hands-on mentorship and structured business development support. Participating companies will work with experienced professionals to evaluate their technologies, identify development priorities and establish realistic plans for advancing toward commercialization.
The program will also help founders assess whether their products and business strategies align with the expectations of healthcare providers, investors and potential commercial partners. This approach is intended to give startups a clearer understanding of the work required to move from technical validation to market readiness.
Dr. Carlos Encinas, Chief Science Officer at EmeraNova, said the accelerator was developed from the recognition that early guidance could help companies avoid some of the difficulties that commonly emerge later in the development process.
“Catalyst came from the notion that if we can come in earlier with these technologies, perhaps we can anticipate and avoid some of the hurdles that startups suffer later on into the process because of lack of knowledge and experience,” Encinas said.
He added that EmeraNova’s interest in identifying new technologies is closely connected to its objective of expanding the solutions available to healthcare providers.
“Our passion lies in identifying new technologies, and through Catalyst we can ensure the best solutions in tissue restoration are adopted into our toolbox and make it into providers’ hands,” he said.
Through this model, EmeraNova intends to strengthen the pathway connecting emerging technology developers with the clinical and commercial expertise needed to bring new products into healthcare settings.
Four-Month Accelerator Built Around Four Development Phases
Catalyst will run for four months and guide participating startups through four structured phases. Each phase is designed to address a different aspect of company and product development, allowing founders to evaluate their current position, identify gaps and prepare for the next stage of growth.
The program will begin with a diagnostic and discovery phase, followed by product and commercialization roadmap development, investor-readiness preparation and a final assessment culminating in Demo Day.
1. Diagnostic and Discovery: Evaluating Technology and Market Potential
The first phase will focus on understanding each participating company’s technology, business model and development position. Founders will work with EmeraNova experts to conduct a comprehensive assessment of the venture and identify areas requiring further attention.
The evaluation will cover several important dimensions, including:
- Technology assessment: Reviewing the underlying innovation, proof-of-concept evidence and development progress.
- Team evaluation: Assessing the capabilities and experience of the founding team and identifying potential expertise gaps.
- Market opportunity: Examining the intended market, potential users, unmet clinical needs and commercial opportunities.
- Intellectual property: Reviewing the company’s intellectual property position and identifying relevant considerations for protecting its innovation.
- Regulatory and clinical readiness: Evaluating the company’s progress toward meeting applicable regulatory and clinical development requirements.
- Investment potential: Considering the venture’s funding needs, commercial prospects and readiness for potential investment discussions.
This initial assessment will provide founders with a clearer picture of their strengths, development challenges and opportunities. It will also help establish priorities for the remaining stages of the accelerator.
2. Product and Commercialization Roadmap: Establishing Priorities
Following the diagnostic assessment, participating startups will work on developing a product and commercialization roadmap.
This phase will translate the findings from the initial evaluation into a structured plan for moving the technology forward. The roadmap will identify key priorities, development milestones and the resources required to achieve them.
For healthcare startups, commercialization planning can involve several interconnected activities. These may include refining product requirements, strengthening clinical and regulatory strategies, identifying manufacturing or operational needs, evaluating potential partnerships and preparing for market entry.
By helping founders organize these activities into a practical development framework, Catalyst aims to make the commercialization process more manageable and provide companies with a clearer understanding of the steps ahead.
The roadmap will also help founders identify where additional expertise, funding or external support may be necessary to meet their objectives.
3. Investor Readiness: Preparing for Funding Opportunities
The third phase will focus on preparing participating companies for investor engagement.
Securing investment is an important consideration for startups developing medical technologies, particularly when products require additional clinical evidence, regulatory work, manufacturing capabilities or commercial infrastructure before market launch.
However, attracting investment involves more than presenting an innovative product. Companies must also communicate their market opportunity, development strategy, financial requirements, intellectual property position and potential for growth.
Catalyst will help founders refine their investment materials and address gaps that could arise during investor due diligence. The program will also support the organization of a data room containing relevant company and development information for potential investor review.
This preparation is intended to help participating startups present their businesses more effectively and respond to the questions investors may raise when evaluating a healthcare technology venture.
By strengthening the quality and organization of investment materials, the accelerator seeks to improve founders’ preparedness for funding discussions and potential strategic partnerships.
4. Final Assessment and Demo Day: Presenting Opportunities to Investors
The final phase will bring together the work completed throughout the four-month program.
Mentors will provide each participating startup with an assessment and executive summary outlining its development progress, opportunities and remaining priorities. Founders will also prepare presentations for the accelerator’s Demo Day.
The program will culminate in a live presentation to EmeraNova leadership, partners and investors. During the event, participating companies will have the opportunity to present their technologies, development strategies and commercialization plans.
The Demo Day will also provide an opportunity for potential investment of up to $200,000 per venture. The investment opportunity is intended to support promising companies as they continue advancing their technologies and pursuing commercialization.
The program’s structure is designed to ensure that startups reach the final presentation with a stronger understanding of their business, clearer development priorities and more organized investment materials.
Mentorship and Practical Guidance at the Center of Catalyst
EmeraNova is positioning Catalyst differently from traditional accelerator models by placing particular emphasis on mentorship, education and detailed development guidance.
While funding can be essential to the progress of an early-stage company, access to capital alone may not resolve the challenges associated with bringing a medical technology to market. Founders must also understand the expectations of healthcare providers, regulatory authorities, investors and commercial partners.
In tissue restoration and advanced wound care, these requirements can be especially complex. Companies may need to demonstrate that their technologies address meaningful clinical needs, establish appropriate evidence, develop viable manufacturing and distribution strategies, and determine how their products can fit into existing healthcare workflows.
Catalyst is intended to help startups address these considerations through direct engagement with experienced professionals. By providing guidance throughout the development process, EmeraNova hopes to help founders make informed decisions and reduce the likelihood of encountering avoidable obstacles at later stages.
The accelerator will also allow EmeraNova to evaluate emerging technologies that could complement its existing portfolio and support its broader objective of expanding access to advanced tissue restoration solutions.
Jaime Leija, President and Chief Executive Officer of EmeraNova, said the initiative was inspired in part by the mentorship he received during his own professional journey.
“I was lucky enough to be mentored by some really savvy businesspeople throughout my journey and career, and so I thought it only made sense for me to pay that forward,” Leija said.
He described Catalyst as an opportunity to provide startup companies with access to knowledge, expertise and resources during important early stages of product development.
“Catalyst gives us a very unique opportunity to aid startup companies in the very early stages of product development and to loan them our knowledge, expertise and resources,” he added.
The program reflects EmeraNova’s view that stronger early-stage support can help promising healthcare technologies progress more effectively through development and toward adoption.
Building on EmeraNova’s Global Technology Partnerships
Catalyst builds on EmeraNova’s existing experience working with companies and technologies across the global tissue restoration and advanced wound care landscape.
Over the past several years, the company has focused on identifying and partnering with technology developers to help commercialize innovative solutions. Its collaborations and technology partnerships have included Kent Imaging, BlueDop, Imbed Biosciences, MimiX, SweetBio, Terraplasma Medical, cureVision and Hyalomatrix.
These relationships reflect EmeraNova’s approach to identifying technologies with potential applications in tissue restoration and supporting their progression toward clinical and commercial use.
The company intends for Catalyst to expand these activities substantially by creating a more structured process for evaluating and supporting emerging innovators. Through the accelerator, EmeraNova will be able to engage with a broader range of startups, assess their technologies and provide development assistance before potential partnerships or commercialization opportunities emerge.
The initiative could also create opportunities for participating companies to benefit from EmeraNova’s experience in product strategy, commercialization and collaboration across the healthcare technology sector.
For startups, access to this type of industry knowledge may help them better understand the practical requirements of bringing new solutions to healthcare markets. For EmeraNova, the program offers a way to identify promising innovations that could contribute to its future technology portfolio.
The company’s longer-term objective is to strengthen the pipeline of advanced tissue restoration solutions and support the development of technologies that address unmet needs in patient care.
Supporting Innovation Across Tissue Restoration and Wound Care
Tissue restoration and advanced wound care represent areas where medical technology innovation can play an important role in improving treatment approaches and supporting patient recovery. Progress in these fields may involve new materials, devices, biological technologies, diagnostic tools and other approaches designed to support tissue repair and restoration.
However, translating these innovations into widely adopted clinical solutions requires coordination across scientific development, clinical evaluation, regulatory planning and commercial execution.
Startups developing these technologies may have strong scientific or technical foundations but limited access to the industry experience required to navigate the later stages of development. Catalyst is intended to address some of these challenges by combining structured assessment with mentorship and potential financial support.
By targeting companies that have already demonstrated proof of concept and progressed beyond the earliest stages of development, EmeraNova aims to work with ventures that have an established technology foundation and are positioned to benefit from more focused commercialization guidance.
The accelerator’s four-month structure will provide a defined period for evaluating each venture, developing actionable plans and preparing for engagement with investors and industry partners.
Although participation does not guarantee investment or commercial success, the program is designed to give startups access to resources and expertise that may help strengthen their readiness for the next stage of growth.
Applications Now Open for Catalyst
EmeraNova has opened applications for Catalyst, inviting eligible startups in medtech, biotech and pharma to apply for participation in the four-month accelerator.
Companies interested in the program can review the application requirements and submit their information through the official application portal. Additional information about the accelerator, its development phases and participation opportunities is available through the Catalyst website.
The program’s combination of technology assessment, commercialization planning, investor preparation and potential investment is intended to support startups seeking to advance innovations in tissue restoration, advanced wound care and regenerative medicine.
For EmeraNova, the launch represents an expansion of its strategy to identify promising healthcare technologies and help bring them closer to clinical and commercial adoption. By combining its existing industry partnerships with a dedicated accelerator, the company aims to create additional pathways for emerging solutions to reach healthcare providers and patients.
More information about the program and applications is available at EmeraNovaCatalyst.com. Startups can also apply through the Catalyst application portal.
About EmeraNova™
EmeraNova™ is a Phoenix-based medical technology company focused on advancing tissue restoration. Through clinician-driven product strategy, entrepreneurial partnerships and rapid commercialization, the company identifies, develops and delivers technologies across healthcare settings.
EmeraNova works with technology innovators and industry partners to support the advancement of solutions in tissue restoration and related areas of care. Its approach emphasizes identifying promising technologies and helping move them toward practical use by healthcare providers.
BLS Labs, LLC and BLS Sales & Marketing, LLC are accredited by the Association for the Advancement of Tissue and Biologics (AATB), reflecting the organization’s commitment to quality, safety and operational excellence.
Through initiatives such as Catalyst, EmeraNova aims to expand its engagement with emerging innovators and strengthen the development and commercialization of advanced tissue restoration technologies.
About Catalyst, An EmeraNova™ Accelerator
Catalyst, An EmeraNova™ Accelerator™, is a four-month strategic accelerator helping startups in tissue restoration and advanced wound care move from scientific innovation toward commercialization. Through hands-on mentorship, technical validation, regulatory and clinical guidance, and industry connections, the program helps founders develop commercialization strategies and strengthen investor readiness. Catalyst supports startups from around the globe, culminating in a Demo Day presentation to leadership, partners, and investors, with potential investment of up to $200,000.